Fragment-based design of novel antiviral agents
Dengue and Zika are mosquito-borne viral infections for which there are currently no specific treatments. The global incidence of both Dengue and Zika has increased dramatically in recent years. We are currently working to develop inhibitors of a number of enzymes that are essential in the life-cycle of these viruses. Our strategy is to use fragment-based screening to identify molecules that bind to the enzymes and then employ structure-guided approaches to elaborate compounds into potent inhibitors for subsequent testing.